Persistent opioid use is associated with worse survival after lobectomy for stage i non-small cell lung cancer.

The incidence of persistent opioid use after lung surgery is high. Although adverse effects by opioids have been well described, it is unknown whether persistent opioid use is associated with worse survival.Patients who received a lobectomy for stage I NSCLC from 2007 - 2013 were identified from the SEER-Medicare database. Opioid use was ascertained through records of prescriptions filled through Part D. Patients were matched 2:1 according to their likelihood of persistent opioid use, which was defined as any opioid prescription filled 3-6 months after surgery.2,884 patients were identified. The incidence of persistent opioid use 3-6 months after surgery was 27.0%. After matching, persistent opioid use was associated with worse overall survival (p<0.001) and cancer-specific survival (p<0.001). Those who used the lowest quartile of opioids, which was often manifested as a single opioid prescription, showed similar overall survival as no opioid use (HR 1.27, 95% CI 0.93 - 1.72). However, the second and third quartile of opioid use were associated with decreased overall survival (HR 1.53, 95% CI 1.14 - 2.03 and HR 1.39, 95% CI 1.04 - 1.86, respectively) that was nonetheless less severe than the highest quartile of opioid use (HR 2.50, 95% CI 1.95 - 3.21). Age, sex, marital status, comorbidity, tumor size, tumor grade and radiation were also associated with worse overall survival, with chemotherapy use and VATS being associated with improved overall survival.Persistent opioid use 3 to 6 months after lobectomy is independently associated with worse overall survival and worse cancer-specific survival.

[1]  L. Svensson,et al.  Trends and Outcomes of Cardiovascular Surgery in Patients With Opioid Use Disorders , 2019, JAMA surgery.

[2]  A. Pockley,et al.  Influence of opioids on immune function in patients with cancer pain: from bench to bedside , 2018, British journal of pharmacology.

[3]  J. Roth,et al.  Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. , 2018, The Annals of thoracic surgery.

[4]  S. Burns,et al.  Association between intraoperative opioid administration and 30‐day readmission: a pre‐specified analysis of registry data from a healthcare network in New England , 2018, British journal of anaesthesia.

[5]  Alexander R. Cortez,et al.  Impact of Preoperative Opioid Use After Emergency General Surgery , 2018, Journal of Gastrointestinal Surgery.

[6]  Lesly A. Dossett,et al.  New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Stephanie E. Moser,et al.  Preoperative Opioid Use is Independently Associated With Increased Costs and Worse Outcomes After Major Abdominal Surgery , 2017, Annals of surgery.

[8]  M. Sherman,et al.  The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship , 2016, The American journal of surgical pathology.

[9]  L. Baker,et al.  Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. , 2016, JAMA internal medicine.

[10]  Bongseog Kim,et al.  Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study , 2016, Korean journal of anesthesiology.

[11]  Jian-hua Zhou,et al.  Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts , 2016, Scientific Reports.

[12]  Andrew T Chan,et al.  Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. , 2015, JAMA.

[13]  T. Ahern,et al.  Opioids and breast cancer recurrence: A Danish population‐based cohort study , 2015, Cancer.

[14]  B. Kissela,et al.  Prescription Opioid Use and Risk of Coronary Heart Disease, Stroke, and Cardiovascular Death Among Adults from a Prospective Cohort (REGARDS Study). , 2015, Pain medicine.

[15]  Teruhiko Yoshida,et al.  Peripheral Opioid Antagonist Enhances the Effect of Anti-Tumor Drug by Blocking a Cell Growth-Suppressive Pathway In Vivo , 2015, PloS one.

[16]  D. Ring,et al.  Preoperative Opioid Misuse is Associated With Increased Morbidity and Mortality After Elective Orthopaedic Surgery , 2015, Clinical orthopaedics and related research.

[17]  F. Peng,et al.  Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer , 2015, Oncotarget.

[18]  E. Li,et al.  Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma. , 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[19]  P. White,et al.  Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. , 2014, British journal of anaesthesia.

[20]  Yunfang Li,et al.  Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. , 2014, British journal of anaesthesia.

[21]  R. Salgia,et al.  Increased μ-opioid receptor expression in metastatic lung cancer. , 2014, British journal of anaesthesia.

[22]  J. Cata,et al.  A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection , 2014, Cancer medicine.

[23]  Sabita Roy,et al.  Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. , 2014, The American journal of pathology.

[24]  R. Salgia,et al.  The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer , 2014, PloS one.

[25]  D. Wijeysundera,et al.  Rates and risk factors for prolonged opioid use after major surgery: population based cohort study , 2014, BMJ : British Medical Journal.

[26]  M. Kuskowski,et al.  Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer , 2013, Cancer.

[27]  C. Bhamidipati,et al.  Tumor recurrence after complete resection for non-small cell lung cancer. , 2012, The Annals of thoracic surgery.

[28]  R. Millikan,et al.  &mgr;-Opioid Receptor Gene A118G Polymorphism Predicts Survival in Patients with Breast Cancer , 2012, Anesthesiology.

[29]  R. Salgia,et al.  Overexpression of the &mgr;-Opioid Receptor in Human Non-Small Cell Lung Cancer Promotes Akt and mTOR Activation, Tumor Growth, and Metastasis , 2012, Anesthesiology.

[30]  K. Gupta,et al.  Influence of Morphine on Pericyte-Endothelial Interaction: Implications for Antiangiogenic Therapy , 2012, Journal of oncology.

[31]  D. Lambert,et al.  Direct effect of morphine on breast cancer cell function in vitro: role of the NET1 gene. , 2011, British journal of anaesthesia.

[32]  R. Kratzke,et al.  Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer , 2011, Anesthesia and analgesia.

[33]  Marcia Valenstein,et al.  Association between Opioid Prescribing Patterns and Opioid Overdose-related Deaths Downloaded From: Http://jama.jamanetwork.com/ by a Penn State Milton S Hershey Med Ctr User on 08/01/2013 , 2022 .

[34]  Chin-Tu Chen,et al.  The Novel Role of the Mu Opioid Receptor in Lung Cancer Progression: A Laboratory Investigation , 2011, Anesthesia and analgesia.

[35]  Sabita Roy,et al.  Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. , 2010, The American journal of pathology.

[36]  R. Salgia,et al.  Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors , 2010, Journal of angiogenesis research.

[37]  B. Kazemi,et al.  Effect of opium use on short-term outcome in patients undergoing coronary artery bypass surgery , 2010, General thoracic and cardiovascular surgery.

[38]  C. Miller,et al.  Risk of Recurrence of Resected Stage I Non-small Cell Lung Cancer in Elderly Patients as Compared with Younger Patients , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  Chong-Zhi Wang,et al.  Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells. , 2009, Anticancer research.

[40]  J. Garcia,et al.  Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor–induced angiogenesis , 2008, Molecular Cancer Therapeutics.

[41]  S. Datta,et al.  Opioid complications and side effects. , 2008, Pain physician.

[42]  C. Song,et al.  COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia , 2007, British Journal of Cancer.

[43]  P. Sacerdote,et al.  Buprenorphine ameliorates the effect of surgery on hypothalamus–pituitary–adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment , 2007, Brain, Behavior, and Immunity.

[44]  J. Garcia,et al.  Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. , 2007, American journal of respiratory cell and molecular biology.

[45]  M. Lingen,et al.  Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. , 2006, Microvascular research.

[46]  Y. Nomoto,et al.  Addition of noradrenaline to intrathecal morphine augments the postoperative suppression of natural killer cell activity , 2004, Journal of Anesthesia.

[47]  P. Sacerdote,et al.  The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats , 2002, Journal of Neuroimmunology.

[48]  D. Yee,et al.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. , 2002, Cancer research.

[49]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[50]  M. Ammatuna,et al.  The Effects of Tramadol and Morphine on Immune Responses and Pain After Surgery in Cancer Patients , 2000, Anesthesia and analgesia.

[51]  F. Benedetti,et al.  Neurophysiologic assessment of nerve impairment in posterolateral and muscle-sparing thoracotomy. , 1998, The Journal of thoracic and cardiovascular surgery.

[52]  F. Benedetti,et al.  Postoperative pain and superficial abdominal reflexes after posterolateral thoracotomy. , 1997, The Annals of thoracic surgery.

[53]  B. Beilin,et al.  Effects of Anesthesia Based on Large Versus Small Doses of Fentanyl on Natural Killer Cell Cytotoxicity in the Perioperative Period , 1996, Anesthesia and analgesia.

[54]  R. Gale,et al.  Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats , 1989, Brain, Behavior, and Immunity.

[55]  S. Cole,et al.  Association of Household Opioid Availability and Prescription Opioid Initiation Among Household Members , 2018, JAMA internal medicine.

[56]  A. Aich,et al.  Could Perioperative Opioid Use Increase the Risk of Cancer Progression and Metastases? , 2016, International anesthesiology clinics.

[57]  J. Meyerhardt,et al.  Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. , 2015, Journal of the National Cancer Institute.

[58]  M. Valenstein,et al.  Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths , 2012 .

[59]  M. Brock,et al.  Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.